While the stock experienced an intraday surge of 506%, the withdrawal of the public offering registration statement and decision not to pursue the offering represents a negative development for the company's capital raising plans. The subsequent 9% after-hours decline and Benzinga's Edge Stock Rankings indicating a negative price trend across all timeframes further support a negative sentiment outlook.
NYSE American · RGNT
Regentis Biomaterials news
$1.85−2.12%
Close Sep 29, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Regentis Biomaterials
BenzingaJun 16, 1:31 AM ET▼ Negative
Also mentions RGNT
Articles that tag RGNT but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology